– USA, NJ – RenovaCare, Inc. (OTC: RCAR), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced that its CEO and President, Alan Rubino has been elected to the additional role of Chairman of the Board of Directors effective October 1, 2020, succeeding Harmel Rayat who resigned from the Board and as Chairman.
Mr. Rubino was named President and CEO, and a member of the Board of Directors, in November 2019 to build a highly experienced leadership team with a proven track record to focus the Company on its planned transition from a pre-clinical stage to a development/commercial-stage entity.
Mr. Rubino stated, “On behalf of the entire RenovaCare organization, I wish to thank Mr. Rayat for his many years of unwavering support and capital investment, crucial for the development of our CellMist™ and SkinGun™ regenerative technology platforms.”
Mr. Rayat commented, “In addition to making a significant investment to finance the development of the Company’s breakthrough technology, I endeavored to find a highly competent CEO that could take RenovaCare to the next level. Over the last year, Alan and his expanded management team have exceeded both the Board’s expectations and mine, and their extensive experience and wide-ranging capabilities have now allowed me to devote more time to my family office portfolio. As a long-time stockholder, I remain an ardent supporter of Alan and his entire team and look forward to the day that the SkinGun™ becomes the treatment of choice for patients everywhere suffering from severe burns and wounds.”
“We wish Mr. Rayat continued success in his future business endeavors,” concluded Mr. Rubino.
About RenovaCare
RenovaCare, Inc. is developing first-of-its-kind autologous stem cell therapies for the regeneration of human organs. Its initial product under development targets the body’s largest organ, the skin. The company’s flagship technology, the CellMist™ System, uses its patented SkinGun to spray a liquid suspension of a patient’s stem cells – the CellMist Solution – onto wounds.
RenovaCare is developing its CellMist System as a promising new alternative for patients suffering from burns, chronic and acute wounds, and scars. In the US alone, this $45 billion market is greater than the spending on high-blood pressure management, cholesterol treatments, and back pain therapeutics.
RenovaCare products are currently in development. They are not available for sale in the United States. There is no assurance that the Company’s planned or filed submissions to the U.S. Food and Drug Administration will be accepted or cleared by the FDA.
For more information: https://www.renovacareinc.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
